A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) vs Intravenous Methylprednisolone (Solu-Medrol) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS).

Trial Profile

A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) vs Intravenous Methylprednisolone (Solu-Medrol) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Prednisolone (Primary) ; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Galapagos NV
  • Most Recent Events

    • 05 Oct 2016 Status changed from suspended to discontinued.
    • 28 Apr 2012 Additional location (Poland) added as reported by European Clinical Trials Database.
    • 21 Apr 2012 Company (Enceladus Pharmaceuticals) added as trial sponsor/affiliate as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top